{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "18",
                "@timestamp": "2023-01-18T05:34:17.000017-05:00",
                "@year": "2023",
                "@month": "01"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2018",
                "@month": "06"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": {
                "xocs:funding-agency-acronym": "NIGMS",
                "xocs:funding-agency": "National Institute of General Medical Sciences",
                "xocs:funding-id": "U54GM104942",
                "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000057",
                "xocs:funding-agency-country": "http://sws.geonames.org/6252001"
            },
            "xocs:funding-addon-generated-timestamp": "2022-03-07T14:52:32.169Z",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60028124",
                            "@country": "usa",
                            "city": "Morgantown",
                            "organization": {"$": "West Virginia University Health Sciences Center"},
                            "affiliation-id": {"@afid": "60028124"},
                            "state": "WV",
                            "@affiliation-instance-id": "2016633710-01ad1c03d7a90276bdc0342ac607f307",
                            "ce:source-text": "West Virginia University Health Sciences Center, Morgantown, WV;"
                        },
                        "author": [{
                            "ce:given-name": "Sally",
                            "preferred-name": {
                                "ce:given-name": "Sally",
                                "ce:initials": "S.",
                                "ce:surname": "Hodder",
                                "ce:indexed-name": "Hodder S."
                            },
                            "@author-instance-id": "2016633710-2a15fdb67747f64a7fb2d34197138a96",
                            "@seq": "1",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Hodder",
                            "@auid": "35558534100",
                            "ce:indexed-name": "Hodder S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60015277",
                            "@country": "usa",
                            "city": "Philadelphia",
                            "organization": [
                                {"$": "Division of Infectious Diseases"},
                                {"$": "Thomas Jefferson University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60015277",
                                "@dptid": "105581626"
                            },
                            "state": "PA",
                            "@affiliation-instance-id": "2016633710-3022e1365cec32e293a752e234cd715f",
                            "ce:source-text": "Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA;",
                            "@dptid": "105581626"
                        },
                        "author": [{
                            "ce:given-name": "Kathleen",
                            "preferred-name": {
                                "ce:given-name": "Kathleen",
                                "ce:initials": "K.",
                                "ce:surname": "Squires",
                                "ce:indexed-name": "Squires K."
                            },
                            "@author-instance-id": "2016633710-af6ac7135aa090a2a8fb1f5995472034",
                            "@seq": "2",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Squires",
                            "@auid": "35394567100",
                            "ce:indexed-name": "Squires K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Uganda",
                            "@afid": "60071691",
                            "@country": "uga",
                            "city": "Kampala",
                            "organization": {"$": "Joint Clinical Research Centre"},
                            "affiliation-id": {"@afid": "60071691"},
                            "@affiliation-instance-id": "2016633710-1074feccebe844c0d563493270090469",
                            "ce:source-text": "Joint Clinical Research Centre, Kampala, Uganda;"
                        },
                        "author": [{
                            "ce:given-name": "Cissy",
                            "preferred-name": {
                                "ce:given-name": "Cissy",
                                "ce:initials": "C.",
                                "ce:surname": "Kityo",
                                "ce:indexed-name": "Kityo C."
                            },
                            "@author-instance-id": "2016633710-bc6401bd6b6b066a806904e703e78820",
                            "@seq": "3",
                            "ce:initials": "C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Kityo",
                            "@auid": "6602918610",
                            "ce:indexed-name": "Kityo C."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "113700425",
                            "@country": "usa",
                            "city": "Savannah",
                            "organization": [
                                {"$": "Georgia Department of Public Health"},
                                {"$": "Coastal Health District"},
                                {"$": "Chatham Care Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "113700425",
                                "@dptid": "129080671"
                            },
                            "state": "GA",
                            "@affiliation-instance-id": "2016633710-abe8b0d69aee6e206c01106cf4b02683",
                            "ce:source-text": "Georgia Department of Public Health, Coastal Health District, Chatham Care Center, Savannah, GA;",
                            "@dptid": "129080671"
                        },
                        "author": [{
                            "ce:given-name": "Debbie",
                            "preferred-name": {
                                "ce:given-name": "Debbie",
                                "ce:initials": "D.",
                                "ce:surname": "Hagins",
                                "ce:indexed-name": "Hagins D."
                            },
                            "@author-instance-id": "2016633710-a755de17a01a0ffce5dd4e3f4029634e",
                            "@seq": "4",
                            "ce:initials": "D.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Hagins",
                            "@auid": "36522862600",
                            "ce:indexed-name": "Hagins D."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60031780",
                            "@country": "tha",
                            "organization": [
                                {"$": "kHIV Netherlands Australia Thailand Research Collaboration"},
                                {"$": "The Thai Red Cross AIDS Research Centre"}
                            ],
                            "affiliation-id": {"@afid": "60031780"},
                            "@affiliation-instance-id": "2016633710-66e737b25d0184796e3764468c1f466e",
                            "ce:source-text": "kHIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre;"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@author-instance-id": "2016633710-93a035776908e11f18bd621a96f54120",
                            "@seq": "5",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD, PhD",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty Of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60002620"},
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "2016633710-04680e88368281308ef2aef5ce18beec",
                            "ce:source-text": "Faculty Of Medicine, Chulalongkorn University, Bangkok, Thailand; and"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@author-instance-id": "2016633710-93a035776908e11f18bd621a96f54120",
                            "@seq": "5",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD, PhD",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002909",
                            "@country": "usa",
                            "city": "Foster City",
                            "organization": [
                                {"$": "Departments of Clinical Research"},
                                {"$": "Biometrics"},
                                {"$": "and Virology"},
                                {"$": "Gilead Sciences"},
                                {"$": "Inc."}
                            ],
                            "affiliation-id": {
                                "@afid": "60002909",
                                "@dptid": "113581462"
                            },
                            "state": "CA",
                            "@affiliation-instance-id": "2016633710-fdfd13baeb0f643e1e01895d8ad18093",
                            "ce:source-text": "Departments of Clinical Research, Biometrics, and Virology, Gilead Sciences, Inc., Foster City, CA.",
                            "@dptid": "113581462"
                        },
                        "author": [
                            {
                                "ce:given-name": "Anna",
                                "preferred-name": {
                                    "ce:given-name": "Anna",
                                    "ce:initials": "A.",
                                    "ce:surname": "Kido",
                                    "ce:indexed-name": "Kido A."
                                },
                                "@author-instance-id": "2016633710-4626bf5d2d8ce80bbde819d876894814",
                                "@seq": "6",
                                "ce:initials": "A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "BS",
                                "ce:surname": "Kido",
                                "@auid": "57208209551",
                                "ce:indexed-name": "Kido A."
                            },
                            {
                                "ce:given-name": "Shuping",
                                "preferred-name": {
                                    "ce:given-name": "Shuping",
                                    "ce:initials": "S.",
                                    "ce:surname": "Jiang",
                                    "ce:indexed-name": "Jiang S."
                                },
                                "@author-instance-id": "2016633710-d5156619de839106579db3e3a71e8dd8",
                                "@seq": "7",
                                "ce:initials": "S.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "PhD",
                                "ce:surname": "Jiang",
                                "@auid": "57189385625",
                                "ce:indexed-name": "Jiang S."
                            },
                            {
                                "ce:given-name": "Rima",
                                "preferred-name": {
                                    "ce:given-name": "Rima",
                                    "ce:initials": "R.",
                                    "ce:surname": "Kulkarni",
                                    "ce:indexed-name": "Kulkarni R."
                                },
                                "@author-instance-id": "2016633710-217f8ccbd3188d900bd4724c65c91f3c",
                                "@seq": "8",
                                "ce:initials": "R.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "BS",
                                "ce:surname": "Kulkarni",
                                "@auid": "54782992500",
                                "ce:indexed-name": "Kulkarni R."
                            },
                            {
                                "ce:given-name": "Andrew",
                                "preferred-name": {
                                    "ce:given-name": "Andrew",
                                    "ce:initials": "A.",
                                    "ce:surname": "Cheng",
                                    "ce:indexed-name": "Cheng A."
                                },
                                "@author-instance-id": "2016633710-404ddefd6e498e04361f04d32477ba92",
                                "@seq": "9",
                                "ce:initials": "A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD, PhD",
                                "ce:surname": "Cheng",
                                "@auid": "7402075263",
                                "ce:indexed-name": "Cheng A."
                            },
                            {
                                "ce:given-name": "Huyen",
                                "preferred-name": {
                                    "ce:given-name": "Huyen",
                                    "ce:initials": "H.",
                                    "ce:surname": "Cao",
                                    "ce:indexed-name": "Cao H."
                                },
                                "@author-instance-id": "2016633710-27a051000d7f3370f1f8f30178072124",
                                "@seq": "10",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Cao",
                                "@auid": "56471119200",
                                "ce:indexed-name": "Cao H."
                            }
                        ]
                    }
                ],
                "citation-title": "Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women",
                "abstracts": "Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.Background: The integrase inhibitor regimen [elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (TDF)] demonstrated superior efficacy when compared with a protease inhibitor regimen [ritonavir-boosted atazanavir (ATV + RTV) and FTC/TDF] in 575 treatment-naive women at week 48. We investigated the efficacy, safety, and tolerability of switching to a TAF-based, single-tablet regimen containing elvitegravir, cobicistat, FTC, and tenofovir alafenamide (E/C/F/TAF) versus remaining on ATV + RTV plus FTC/TDF. Methods: After completing the initial randomized, blinded phase, virologically suppressed (HIV-1 RNA <50 copies/mL) women on ATV + RTV plus FTC/TDF were rerandomized (3:1) to receive open-label E/C/F/TAF versus remaining on their current regimen. The primary end point was proportion of participants with plasma HIV-1 RNA <50 copies per milliliter at week 48 (U.S. FDA snapshot algorithm), with a prespecified noninferiority margin of 12%. Safety [adverse events (AEs)] and tolerability were also assessed. Results: Of 575 women originally randomized and treated in the blinded phase, 159 were rerandomized to switch to E/C/F/TAF and 53 to remain on ATV + RTV plus FTC/TDF. At week 48, virologic suppression was maintained in 150 (94%) of women on E/C/F/TAF and 46 (87%) on ATV + RTV plus FTC/TDF [difference 7.5% (95% confidence interval -1.2% to 19.4%)], demonstrating noninferiority of E/C/F/TAF to ATV + RTV and FTC/TDF. Incidence of AEs was similar between groups; study drug\u2013related AEs were more common with E/C/F/TAF (11% versus 4%). Conclusions: Switching to E/C/F/TAF was noninferior to continuing ATV + RTV plus FTC/TDF in maintaining virologic suppression and was well tolerated at 48 weeks.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "address-part": "333 Lakeside Drive",
                        "postal-code": "94404",
                        "@country": "usa",
                        "city": "Foster City",
                        "organization": [
                            {"$": "Gilead Sciences"},
                            {"$": "Inc."}
                        ],
                        "state": "CA",
                        "ce:source-text": "Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404"
                    },
                    "person": {
                        "ce:given-name": "Huyen",
                        "ce:initials": "H.",
                        "ce:degrees": "MD",
                        "ce:surname": "Cao",
                        "ce:indexed-name": "Cao H."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "HIV",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "INSTI",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "TAF",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Tenofovir",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Women",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "cp"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://journals.lww.com/jaids/pages/default.aspx",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Journal of Acquired Immune Deficiency Syndromes",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "78",
                            "@issue": "2"
                        },
                        "pagerange": {
                            "@first": "209",
                            "@last": "213"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Journal of Acquired Immune Deficiency Syndromes",
                    "publicationdate": {
                        "month": "06",
                        "year": "2018",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "1 June 2018"
                        },
                        "day": "01"
                    },
                    "codencode": "JJASF",
                    "sourcetitle-abbrev": "J. Acquired Immune Defic. Syndr.",
                    "@country": "usa",
                    "issn": [
                        {
                            "$": "10779450",
                            "@type": "electronic"
                        },
                        {
                            "$": "15254135",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2018"},
                    "publisher": {"publishername": "Lippincott Williams and Wilkins"},
                    "@srcid": "15300154823"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2725"},
                                {"$": "2736"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "1004316-88-4",
                                    "chemical-name": "cobicistat"
                                },
                                {
                                    "cas-registry-number": "1430117-57-9",
                                    "chemical-name": "cobicistat plus elvitegravir plus emtricitabine plus tenofovir disoproxil"
                                },
                                {
                                    "cas-registry-number": "697761-98-1",
                                    "chemical-name": "elvitegravir"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "22177-51-1"},
                                        {"$": "2922-28-3"},
                                        {"$": "73-24-5"}
                                    ],
                                    "chemical-name": "adenine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "137530-41-7"},
                                        {"$": "143491-54-7"},
                                        {"$": "143491-57-0"}
                                    ],
                                    "chemical-name": "emtricitabine"
                                },
                                {
                                    "cas-registry-number": "37205-61-1",
                                    "chemical-name": "proteinase inhibitor"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Adenine"},
                                {"chemical-name": "Anti-HIV Agents"},
                                {"chemical-name": "Cobicistat"},
                                {"chemical-name": "Drug Combinations"},
                                {"chemical-name": "Emtricitabine"},
                                {"chemical-name": "GS-7340"},
                                {"chemical-name": "Integrase Inhibitors"},
                                {"chemical-name": "JTK 303"},
                                {"chemical-name": "Protease Inhibitors"},
                                {"chemical-name": "Quinolones"},
                                {"chemical-name": "RNA, Viral"}
                            ]
                        }
                    ]}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "CABS"},
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "17",
                    "@timestamp": "BST 03:31:24",
                    "@year": "2023",
                    "@month": "01"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2016633710",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "627153668",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "2022009774",
                            "@idtype": "CABS"
                        },
                        {
                            "$": "938313077",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220108326",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "29481486",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20220315856",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20220422572",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "2022900123731X",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85055966450",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85055966450",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "627153668",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "77780299",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1097/QAI.0000000000001663"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "19",
                "reference": [
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infectedadults and Adolescents. Department of Health and Human Services; 2016. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adul-tandAdolescentGL.pdf. Accessed October 11, 2016.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.aidsinfo.nih.gov/ContentFiles/Adul-tandAdolescentGL.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "84855616052",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Department of Health and Human Services; Accessed October 11, 2016",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Panel on Antiretroviral Guidelines for Adults and Adolescents",
                                "ce:indexed-name": "Panel on Antiretroviral Guidelines for Adults and Adolescents"
                            }},
                            "ref-sourcetitle": "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infectedadults and Adolescents"
                        },
                        "ce:source-text": "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infectedadults and Adolescents. Department of Health and Human Services; 2016. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adul-tandAdolescentGL.pdf. Accessed October 11, 2016."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2016; 316:191\u2013210.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84978371920",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "316"},
                                "pagerange": {
                                    "@first": "191",
                                    "@last": "210"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "HF",
                                        "@_fa": "true",
                                        "ce:surname": "Günthard",
                                        "ce:indexed-name": "Gunthard HF"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MS",
                                        "@_fa": "true",
                                        "ce:surname": "Saag",
                                        "ce:indexed-name": "Saag MS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "CA",
                                        "@_fa": "true",
                                        "ce:surname": "Benson",
                                        "ce:indexed-name": "Benson CA"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA"
                        },
                        "ce:source-text": "Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2016; 316:191\u2013210."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "European AIDS Clinical Society (EACS). European Guidelines for Treatment of HIV-positive Adults in Europe, Version 8.2; 2017. Available at: http://www.eacsociety.org/files/guidelines_8.2-english.pdf. Accessed May 12, 2016.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.eacsociety.org/files/guidelines_8.2-english.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": {
                                "$": "85032796214",
                                "@idtype": "SGR"
                            }},
                            "ref-text": "Version 8.2; Accessed May 12, 2016",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "European AIDS Clinical Society (EACS)",
                                "ce:indexed-name": "European AIDS Clinical Society (EACS)"
                            }},
                            "ref-sourcetitle": "European Guidelines for Treatment of HIV-positive Adults in Europe"
                        },
                        "ce:source-text": "European AIDS Clinical Society (EACS). European Guidelines for Treatment of HIV-positive Adults in Europe, Version 8.2; 2017. Available at: http://www.eacsociety.org/files/guidelines_8.2-english.pdf. Accessed May 12, 2016."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Ruane PJ, Dejesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449\u2013455.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84880229518",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "63"},
                                "pagerange": {
                                    "@first": "449",
                                    "@last": "455"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "PJ",
                                        "@_fa": "true",
                                        "ce:surname": "Ruane",
                                        "ce:indexed-name": "Ruane PJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E",
                                        "@_fa": "true",
                                        "ce:surname": "Dejesus",
                                        "ce:indexed-name": "Dejesus E"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger D"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Ruane PJ, Dejesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449\u2013455."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385:2606\u20132615.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84937215233",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "385"},
                                "pagerange": {
                                    "@first": "2606",
                                    "@last": "2615"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "PE",
                                        "@_fa": "true",
                                        "ce:surname": "Sax",
                                        "ce:indexed-name": "Sax PE"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Wohl",
                                        "ce:indexed-name": "Wohl D"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "MT",
                                        "@_fa": "true",
                                        "ce:surname": "Yin",
                                        "ce:indexed-name": "Yin MT"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385:2606\u20132615."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study. Lancet Infect Dis. 2016;16:43\u201352.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85028245571",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "16"},
                                "pagerange": {
                                    "@first": "43",
                                    "@last": "52"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Mills",
                                        "ce:indexed-name": "Mills A"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "JR",
                                        "@_fa": "true",
                                        "ce:surname": "Arribas",
                                        "ce:indexed-name": "Arribas JR"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Andrade-Villanueva",
                                        "ce:indexed-name": "Andrade-Villanueva J"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Infect Dis"
                        },
                        "ce:source-text": "Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study. Lancet Infect Dis. 2016;16:43\u201352."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158\u201365.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84960824872",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {
                                    "@first": "e158",
                                    "@last": "e165"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JE",
                                        "@_fa": "true",
                                        "ce:surname": "Gallant",
                                        "ce:indexed-name": "Gallant JE"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "ES",
                                        "@_fa": "true",
                                        "ce:surname": "Daar",
                                        "ce:indexed-name": "Daar ES"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Raffi",
                                        "ce:indexed-name": "Raffi F"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158\u201365."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3: e410\u201320.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84969972261",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "3"},
                                "pagerange": {
                                    "@first": "e410",
                                    "@last": "e420"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Squires",
                                        "ce:indexed-name": "Squires K"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Kityo",
                                        "ce:indexed-name": "Kityo C"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Hodder",
                                        "ce:indexed-name": "Hodder S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3: e410\u201320."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Smith F, Hammerstorm T, Soon G, et al. A meta-analysis to assess the FDA DAVP\u2019s TLOVR algorithm in HIV submissions. Drug Inf J. 2011; 45:291\u2013300.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "A meta-analysis to assess the FDA DAVP\u2019s TLOVR algorithm in HIV submissions"},
                            "refd-itemidlist": {"itemid": {
                                "$": "80051818332",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "45"},
                                "pagerange": {
                                    "@first": "291",
                                    "@last": "300"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith F"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Hammerstorm",
                                        "ce:indexed-name": "Hammerstorm T"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Soon",
                                        "ce:indexed-name": "Soon G"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Drug Inf J"
                        },
                        "ce:source-text": "Smith F, Hammerstorm T, Soon G, et al. A meta-analysis to assess the FDA DAVP\u2019s TLOVR algorithm in HIV submissions. Drug Inf J. 2011; 45:291\u2013300."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. J Acquir Immune Defic Syndr. 2016;71:530\u2013537.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84949035010",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "71"},
                                "pagerange": {
                                    "@first": "530",
                                    "@last": "537"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Pozniak",
                                        "ce:indexed-name": "Pozniak A"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "JR",
                                        "@_fa": "true",
                                        "ce:surname": "Arribas",
                                        "ce:indexed-name": "Arribas JR"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Gathe",
                                        "ce:indexed-name": "Gathe J"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. J Acquir Immune Defic Syndr. 2016;71:530\u2013537."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93:861\u2013868.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "Bone mineral density changes during the menopause transition in a multiethnic cohort of women"},
                            "refd-itemidlist": {"itemid": {
                                "$": "40849119752",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "93"},
                                "pagerange": {
                                    "@first": "861",
                                    "@last": "868"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JS",
                                        "@_fa": "true",
                                        "ce:surname": "Finkelstein",
                                        "ce:indexed-name": "Finkelstein JS"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "SE",
                                        "@_fa": "true",
                                        "ce:surname": "Brockwell",
                                        "ce:indexed-name": "Brockwell SE"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V",
                                        "@_fa": "true",
                                        "ce:surname": "Mehta",
                                        "ce:indexed-name": "Mehta V"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Endocrinol Metab"
                        },
                        "ce:source-text": "Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93:861\u2013868."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients. Am J Kidney Dis. 2011;57:773\u2013780.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Tenofovir-associated kidney toxicity in HIV-infected patients"},
                            "refd-itemidlist": {"itemid": {
                                "$": "79954611097",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "57"},
                                "pagerange": {
                                    "@first": "773",
                                    "@last": "780"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "AM",
                                        "@_fa": "true",
                                        "ce:surname": "Hall",
                                        "ce:indexed-name": "Hall AM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "BM",
                                        "@_fa": "true",
                                        "ce:surname": "Hendry",
                                        "ce:indexed-name": "Hendry BM"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Nitsch",
                                        "ce:indexed-name": "Nitsch D"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am J Kidney Dis"
                        },
                        "ce:source-text": "Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients. Am J Kidney Dis. 2011;57:773\u2013780."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Nisjijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014; 28:1903\u20131910.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84906536813",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "28"},
                                "pagerange": {
                                    "@first": "1903",
                                    "@last": "1910"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Nisjijima",
                                        "ce:indexed-name": "Nisjijima T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y",
                                        "@_fa": "true",
                                        "ce:surname": "Kawasaki",
                                        "ce:indexed-name": "Kawasaki Y"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Tanaka",
                                        "ce:indexed-name": "Tanaka N"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Nisjijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014; 28:1903\u20131910."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009; 25:387\u2013394.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Progressive renal tubular dysfunction associated with long-term use of tenofovir DF"},
                            "refd-itemidlist": {"itemid": {
                                "$": "64849114382",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "387",
                                    "@last": "394"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "E",
                                    "@_fa": "true",
                                    "ce:surname": "Kinai",
                                    "ce:indexed-name": "Kinai E"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Hanabusa",
                                    "ce:indexed-name": "Hanabusa H."
                                }
                            ]},
                            "ref-sourcetitle": "AIDS Res Hum Retroviruses"
                        },
                        "ce:source-text": "Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009; 25:387\u2013394."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59:e96\u2013138.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84913552378",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "59"},
                                "pagerange": {
                                    "@first": "e96",
                                    "@last": "138"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "GM",
                                        "@_fa": "true",
                                        "ce:surname": "Lucas",
                                        "ce:indexed-name": "Lucas GM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "MJ",
                                        "@_fa": "true",
                                        "ce:surname": "Ross",
                                        "ce:indexed-name": "Ross MJ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "PG",
                                        "@_fa": "true",
                                        "ce:surname": "Stock",
                                        "ce:indexed-name": "Stock PG"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59:e96\u2013138."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, cross-over, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403\u2013408.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "The lipid-lowering effect of tenofovir/emtricitabine: a randomized, cross-over, double-blind, placebo-controlled trial"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84938585202",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "61"},
                                "pagerange": {
                                    "@first": "403",
                                    "@last": "408"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JR",
                                        "@_fa": "true",
                                        "ce:surname": "Santos",
                                        "ce:indexed-name": "Santos JR"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Saumoy",
                                        "ce:indexed-name": "Saumoy M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Curran",
                                        "ce:indexed-name": "Curran A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, cross-over, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403\u2013408."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781\u20131784.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206"},
                            "refd-itemidlist": {"itemid": {
                                "$": "77954319572",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "24"},
                                "pagerange": {
                                    "@first": "1781",
                                    "@last": "1784"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Tungsiripat",
                                        "ce:indexed-name": "Tungsiripat M"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Kitch",
                                        "ce:indexed-name": "Kitch D"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "MJ",
                                        "@_fa": "true",
                                        "ce:surname": "Glesby",
                                        "ce:indexed-name": "Glesby MJ"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781\u20131784."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25:185\u2013195.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care"},
                            "refd-itemidlist": {"itemid": {
                                "$": "78650902667",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "25"},
                                "pagerange": {
                                    "@first": "185",
                                    "@last": "195"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "HM",
                                        "@_fa": "true",
                                        "ce:surname": "Crane",
                                        "ce:indexed-name": "Crane HM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Grunfeld",
                                        "ce:indexed-name": "Grunfeld C"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "JH",
                                        "@_fa": "true",
                                        "ce:surname": "Willig",
                                        "ce:indexed-name": "Willig JH"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25:185\u2013195."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757\u2013765.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention"},
                            "refd-itemidlist": {"itemid": {
                                "$": "74049089108",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "757",
                                    "@last": "765"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Millán",
                                        "ce:indexed-name": "Millan J"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X",
                                        "@_fa": "true",
                                        "ce:surname": "Pintó",
                                        "ce:indexed-name": "Pinto X"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Muñoz",
                                        "ce:indexed-name": "Munoz A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Vasc Health Risk Manag"
                        },
                        "ce:source-text": "Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757\u2013765."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Kampala",
            "@id": "60071691",
            "affilname": "Joint Clinical Research Center Uganda",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691",
            "affiliation-country": "Uganda"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Morgantown",
            "@id": "60028124",
            "affilname": "WVU Health Sciences Center Morgantown",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028124",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Philadelphia",
            "@id": "60015277",
            "affilname": "Thomas Jefferson University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015277",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Foster City",
            "@id": "60002909",
            "affilname": "Gilead Sciences Incorporated",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Savannah",
            "@id": "113700425",
            "affilname": "Chatham Care Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113700425",
            "affiliation-country": "United States"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85055966450",
        "dc:description": "Background: The integrase inhibitor regimen [elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (TDF)] demonstrated superior efficacy when compared with a protease inhibitor regimen [ritonavir-boosted atazanavir (ATV + RTV) and FTC/TDF] in 575 treatment-naive women at week 48. We investigated the efficacy, safety, and tolerability of switching to a TAF-based, single-tablet regimen containing elvitegravir, cobicistat, FTC, and tenofovir alafenamide (E/C/F/TAF) versus remaining on ATV + RTV plus FTC/TDF. Methods: After completing the initial randomized, blinded phase, virologically suppressed (HIV-1 RNA <50 copies/mL) women on ATV + RTV plus FTC/TDF were rerandomized (3:1) to receive open-label E/C/F/TAF versus remaining on their current regimen. The primary end point was proportion of participants with plasma HIV-1 RNA <50 copies per milliliter at week 48 (U.S. FDA snapshot algorithm), with a prespecified noninferiority margin of 12%. Safety [adverse events (AEs)] and tolerability were also assessed. Results: Of 575 women originally randomized and treated in the blinded phase, 159 were rerandomized to switch to E/C/F/TAF and 53 to remain on ATV + RTV plus FTC/TDF. At week 48, virologic suppression was maintained in 150 (94%) of women on E/C/F/TAF and 46 (87%) on ATV + RTV plus FTC/TDF [difference 7.5% (95% confidence interval -1.2% to 19.4%)], demonstrating noninferiority of E/C/F/TAF to ATV + RTV and FTC/TDF. Incidence of AEs was similar between groups; study drug\u2013related AEs were more common with E/C/F/TAF (11% versus 4%). Conclusions: Switching to E/C/F/TAF was noninferior to continuing ATV + RTV plus FTC/TDF in maintaining virologic suppression and was well tolerated at 48 weeks.",
        "pubmed-id": "29481486",
        "prism:coverDate": "2018-06-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85055966450",
        "dc:creator": {"author": [{
            "ce:given-name": "Sally",
            "preferred-name": {
                "ce:given-name": "Sally",
                "ce:initials": "S.",
                "ce:surname": "Hodder",
                "ce:indexed-name": "Hodder S."
            },
            "@seq": "1",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028124",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028124"
            },
            "ce:degrees": "MD",
            "ce:surname": "Hodder",
            "@auid": "35558534100",
            "author-url": "https://api.elsevier.com/content/author/author_id/35558534100",
            "ce:indexed-name": "Hodder S."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85055966450"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055966450&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85055966450&origin=inward"
            }
        ],
        "source-id": "15300154823",
        "citedby-count": "14",
        "prism:volume": "78",
        "subtype": "cp",
        "dc:title": "Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women",
        "openaccess": "1",
        "prism:issn": "10779450 15254135",
        "publishercopyright": "Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.",
        "prism:issueIdentifier": "2",
        "subtypeDescription": "Conference Paper",
        "prism:publicationName": "Journal of Acquired Immune Deficiency Syndromes",
        "prism:pageRange": "209-213",
        "prism:endingPage": "213",
        "openaccessFlag": "true",
        "prism:doi": "10.1097/QAI.0000000000001663",
        "prism:startingPage": "209",
        "dc:identifier": "SCOPUS_ID:85055966450",
        "dc:publisher": "Lippincott Williams and Wilkins"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Adenine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Adult",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Anti-HIV Agents",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Antiretroviral Therapy, Highly Active",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Cobicistat",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Double-Blind Method",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Drug Combinations",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Drug Resistance, Viral",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Drug-Related Side Effects and Adverse Reactions",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Emtricitabine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Female",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "HIV Infections",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "HIV-1",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Integrase Inhibitors",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Protease Inhibitors",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Quinolones",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "RNA, Viral",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "HIV"
        },
        {
            "@_fa": "true",
            "$": "INSTI"
        },
        {
            "@_fa": "true",
            "$": "TAF"
        },
        {
            "@_fa": "true",
            "$": "Tenofovir"
        },
        {
            "@_fa": "true",
            "$": "Women"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Sally",
            "preferred-name": {
                "ce:given-name": "Sally",
                "ce:initials": "S.",
                "ce:surname": "Hodder",
                "ce:indexed-name": "Hodder S."
            },
            "@seq": "1",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60028124",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028124"
            },
            "ce:degrees": "MD",
            "ce:surname": "Hodder",
            "@auid": "35558534100",
            "author-url": "https://api.elsevier.com/content/author/author_id/35558534100",
            "ce:indexed-name": "Hodder S."
        },
        {
            "ce:given-name": "Kathleen",
            "preferred-name": {
                "ce:given-name": "Kathleen",
                "ce:initials": "K.",
                "ce:surname": "Squires",
                "ce:indexed-name": "Squires K."
            },
            "@seq": "2",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015277",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015277"
            },
            "ce:degrees": "MD",
            "ce:surname": "Squires",
            "@auid": "35394567100",
            "author-url": "https://api.elsevier.com/content/author/author_id/35394567100",
            "ce:indexed-name": "Squires K."
        },
        {
            "ce:given-name": "Cissy",
            "preferred-name": {
                "ce:given-name": "Cissy",
                "ce:initials": "C.",
                "ce:surname": "Kityo",
                "ce:indexed-name": "Kityo C."
            },
            "@seq": "3",
            "ce:initials": "C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60071691",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691"
            },
            "ce:degrees": "MD",
            "ce:surname": "Kityo",
            "@auid": "6602918610",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602918610",
            "ce:indexed-name": "Kityo C."
        },
        {
            "ce:given-name": "Debbie",
            "preferred-name": {
                "ce:given-name": "Debbie",
                "ce:initials": "D.",
                "ce:surname": "Hagins",
                "ce:indexed-name": "Hagins D."
            },
            "@seq": "4",
            "ce:initials": "D.",
            "@_fa": "true",
            "affiliation": {
                "@id": "113700425",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113700425"
            },
            "ce:degrees": "MD",
            "ce:surname": "Hagins",
            "@auid": "36522862600",
            "author-url": "https://api.elsevier.com/content/author/author_id/36522862600",
            "ce:indexed-name": "Hagins D."
        },
        {
            "ce:given-name": "Anchalee",
            "preferred-name": {
                "ce:given-name": "Anchalee",
                "ce:initials": "A.",
                "ce:surname": "Avihingsanon",
                "ce:indexed-name": "Avihingsanon A."
            },
            "@seq": "5",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60031780",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:degrees": "MD, PhD",
            "ce:surname": "Avihingsanon",
            "@auid": "57196347321",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196347321",
            "ce:indexed-name": "Avihingsanon A."
        },
        {
            "ce:given-name": "Anna",
            "preferred-name": {
                "ce:given-name": "Anna",
                "ce:initials": "A.",
                "ce:surname": "Kido",
                "ce:indexed-name": "Kido A."
            },
            "@seq": "6",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "BS",
            "ce:surname": "Kido",
            "@auid": "57208209551",
            "author-url": "https://api.elsevier.com/content/author/author_id/57208209551",
            "ce:indexed-name": "Kido A."
        },
        {
            "ce:given-name": "Shuping",
            "preferred-name": {
                "ce:given-name": "Shuping",
                "ce:initials": "S.",
                "ce:surname": "Jiang",
                "ce:indexed-name": "Jiang S."
            },
            "@seq": "7",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "PhD",
            "ce:surname": "Jiang",
            "@auid": "57189385625",
            "author-url": "https://api.elsevier.com/content/author/author_id/57189385625",
            "ce:indexed-name": "Jiang S."
        },
        {
            "ce:given-name": "Rima",
            "preferred-name": {
                "ce:given-name": "Rima",
                "ce:initials": "R.",
                "ce:surname": "Kulkarni",
                "ce:indexed-name": "Kulkarni R."
            },
            "@seq": "8",
            "ce:initials": "R.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "BS",
            "ce:surname": "Kulkarni",
            "@auid": "54782992500",
            "author-url": "https://api.elsevier.com/content/author/author_id/54782992500",
            "ce:indexed-name": "Kulkarni R."
        },
        {
            "ce:given-name": "Andrew",
            "preferred-name": {
                "ce:given-name": "Andrew",
                "ce:initials": "A.",
                "ce:surname": "Cheng",
                "ce:indexed-name": "Cheng A."
            },
            "@seq": "9",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "MD, PhD",
            "ce:surname": "Cheng",
            "@auid": "7402075263",
            "author-url": "https://api.elsevier.com/content/author/author_id/7402075263",
            "ce:indexed-name": "Cheng A."
        },
        {
            "ce:given-name": "Huyen",
            "preferred-name": {
                "ce:given-name": "Huyen",
                "ce:initials": "H.",
                "ce:surname": "Cao",
                "ce:indexed-name": "Cao H."
            },
            "@seq": "10",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:degrees": "MD",
            "ce:surname": "Cao",
            "@auid": "56471119200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56471119200",
            "ce:indexed-name": "Cao H."
        }
    ]}
}}